3-Iodothyronamine, a Novel Endogenous Modulator of Transient Receptor Potential Melastatin 8?

Noushafarin Khajavi1*, Stefan Mergler2 and Heike Biebermann1

1Institute for Experimental Pediatric Endocrinology, Charité University of Medicine Berlin, Berlin, Germany; 2Department of Ophthalmology, Charité University of Medicine Berlin, Berlin, Germany

The decarboxylated and deiodinated thyroid hormone (TH) derivative, 3-iodothyronamine (3-T1AM), is suggested to be involved in energy metabolism and thermoregulation. G protein-coupled receptors (GPCRs) are known as the main targets for 3-T1AM; however, transient receptor potential channels (TRPs) were also recently identified as new targets of 3-T1AM. This article reviews the current knowledge of a putative novel role of 3-T1AM in the modulation of TRPs. Specifically, the TRP melastatin 8 (TRPM8) was identified as a target of 3-T1AM in different cell types including neoplastic cells, whereby 3-T1AM significantly increased cytosolic Ca2+ through TRPM8 activation. Similarly, the β-adrenergic receptor is involved in 3-T1AM-induced Ca2+ influx. Therefore, it has been suggested that 3-T1AM-induced Ca2+ mobilization might be due to β-adrenergic receptor/TRPM8 channel interaction, which adds to the complexity of GPCR regulation by TRPs. It has been revealed that TRPM8 activation leads to a decline in TRPV1 activity, which may be of therapeutic benefit in clinical circumstances such as treatment of TRPV1-mediated inflammatory hyperalgesia, colitis, and dry eye syndrome. This review also summarizes the inverse association between changes in TRPM8 and TRPV1 activity after 3-T1AM stimulation. This finding prompted further detailed investigations of the interplay between 3-T1AM and the GPCR/TRPM8 axis and indicated the probability of additional GPCR/TRP constellations that are modulated by this TH derivative.

Keywords: 3-iodothyronamine, transient receptor potential channel, calcium, thermoregulation, inflammation

INTRODUCTION

Thyronamines (TAMS) are identified as a novel class of endogenous signaling compounds. Currently, two representatives of TAMS, known as 3-iodothyronamine (3-T1AM) and thyronamine (T0AM), have been identified in vivo. Both compounds were detected in blood, heart, brain, thyroid, and many other tissues in rodents (1). Although endogenous TAM concentration may be lower compared to thyroid hormone (TH), it is noteworthy that the tissue-specific and subcellular distributions of TAMS are unknown. Therefore, the concentrations within different cell types might be higher than the average whole tissue concentrations measured.

3-Iodothyronamine is a decarboxylated and deiodinated TH metabolite (2–4). Administration of 3-T1AM in mice resulted in concentration-dependent reversible effects on body temperature, energy metabolism, and cardiac and neurological functions compared with vehicle-treated controls (1). The discovery of 3-T1AM and the profound pharmacological effects of this endogenous signaling compound have raised interest to elucidate its signaling properties (1, 3). It is now known that 3-T1AM is...
a “multi-target” ligand, which affects G protein-coupled receptors (GPCRs) and interacts with non-GPCR proteins (5). Classically, the first GPCR-target identified for 3-T1AM was a member of the rhodopsin-like family of GPCRs known as trace amine-associated receptor 1 (TAAR1) (1) (Figure 1). Recently, several other GPCRs were identified as targets for 3-T1AM, such as α2A adrenergic receptor (6) and β2 adrenergic receptor (7) (Figure 1).

The overall aim of this review is to summarize the modulation of transient receptor potential channels (TRPs) through 3-T1AM. Here, we first review the signaling effects of 3-T1AM and then focus on TRPs as potential targets for this TH metabolite. In particular, two thermo-TRPs, TRP melastatin 8 (TRPM8) and TRPV, are involved in 3-T1AM-induced Ca2+ mobilization. Interestingly, both of these TRPs are the key players in thermoregulation and also mediate inflammation in pathophysiological conditions. In this review, we also describe the 3-T1AM action on a GPCR/TRP interplay and the possible inverse association between changes in different TRP channel activity modulated by this TH metabolite.

### 3-T1AM Declines Body Temperature in Rodents

*In vivo*, 3-T1AM partially opposes effects of classical TH action, resulting in a variety of physiological responses (5). Intraperitoneal (ip) injection of 3-T1AM blocks the hypothalamic–pituitary–thyroid axis and was shown to reversibly decrease metabolic rate in rodents (1, 8). One of the most prominent effects of 3-T1AM in rodents is temporary body temperature decline (1). In clinical settings, this TH metabolite is the only endogenous compound known to induce hypothermia and is additionally suggested to have therapeutic potential for the treatment and prevention of stroke. An ip injection of 3-T1AM in adult mice after the experimental induction of stroke led to a reduction of infarct volumes compared with vehicle-treated control mice (9). Due to the profound effects of 3-T1AM *in vivo*, an increasing number of studies over the last few years have been devoted to investigate the biosynthetic pathways, functions, and underlying mechanisms behind the effects of 3-T1AM.

### Signaling Effects of 3-T1AM

Recent studies described the signaling properties of 3-T1AM in various cell systems. Interestingly, one study revealed that the functional thyrotropin (TSH)-dependent iodide uptake and TSH-dependent mRNA of sodium/iodide symporter in rat thyrocytes were decreased in the presence of 3-T1AM. Therefore, it was congruent to investigate whether 3-T1AM modifies signaling pathways downstream of TSH receptor (TSHR) (10). TSH is the major regulator of thyroid function and activation of the TSHR results in Gs as well as Gq signaling in thyrocytes (11, 12). TSH elicits increases of intracellular Ca2+ concentration through activation of TSHR-mediated Gq signaling (13). This increase partially occurs through inositol 1,4,5-trisphosphate (IP3)-evoked release of Ca2+ sequestered in the endoplasmic reticulum (ER) (14). Previous studies demonstrated the expression of a member of the TRPC family of cation channels known as TRPC2 (pseudogene in human) in rat thyroid cells (15).
Surprisingly, reducing the expression of TRPC2 with shRNA decreased Ca\(^{2+}\) influx and increased the TSH-induced production of cAMP, which can be due to marked upregulation of TSHR. Nevertheless, this study could not rule out the possibility of Gi signaling inhibition. It has been suggested that deprivation of Ca\(^{2+}\) removes the inhibitory action on adenylyl cyclase (AC), upregulates pERK1/2, and increases TSHR expression in thyroid cells (15).

It is known that 3-T\(_1\)AM induces Gs/AC signaling in rat Taar1 and human TAAR1-transfected human embryonic kidney (HEK) cells (1, 16). Recently, it was demonstrated for the first time that 3-T\(_1\)AM increases intracellular Ca\(^{2+}\) concentration in rat thyrocytes (PCCL3 cells) (10). TSH-dependent activation of the Gs signaling pathway was not influenced by 3-T\(_1\)AM (10). Furthermore, there is currently no evidence that 3-T\(_1\)AM induced IP3 formation in thyrocytes (10). However, 3-T\(_1\)AM induced increases in cytosolic Ca\(^{2+}\) under extracellular Ca\(^{2+}\) free conditions in epithelial cells, indicating that the intracellular store depletion independent from Gq downstream signaling (17). Therefore, it was concluded that 3-T\(_1\)AM effect in thyrocytes is independent from TSH-induced Gs or Gq signaling (10).

Beside a function of 3-T\(_1\)AM on thyrocytes, it could be shown in another study that 3-T\(_1\)AM enhanced Gs signaling in response to isoprenaline (ISO) stimulation of the β2-adrenergic receptor in transfected HEK293 cells, but not of β1-adrenergic receptor. Increasing concentrations of 3-T\(_1\)AM in combination with a constant concentration of ISO modulated Gs-mediated cAMP accumulation. At high 3-T\(_1\)AM concentrations (10\(^{-5}\)-10\(^{-6}\) M), there was a weak increase in ISO-stimulated cAMP accumulation. In contrast, at lower 3-T\(_1\)AM concentrations (10\(^{-7}\)-10\(^{-8}\) M), a significant increase in ISO-stimulated cAMP accumulation was observed, which may be related to the activation of G\(_\text{i}\) signaling (7). These findings in in vitro systems indicated that 3-T\(_1\)AM may have a differential impact on certain GPCRs, particularly aminergic receptors, and that the mode of action is concentration dependent. It may also indicate the possibility of biphasic activation (i.e., high and low concentrations may have similar actions, while moderate concentrations enact distinct effects) of different signaling pathways.

Taken together, these studies revealed that 3-T\(_1\)AM enhances GPCR-mediated downstream signaling in different cell types. In addition, β2-adrenergic receptors have been suggested as a new GPCR target for 3-T\(_1\)AM. Nevertheless, the underlying mechanism behind the Ca\(^{2+}\) signal transduction remained elusive.

### ION CHANNELS AS POTENTIAL TARGETS FOR 3-T\(_1\)AM

Although many studies have reported remarkable hypothermia caused by 3-T\(_1\)AM, different observations demonstrated that this effect is not exclusively mediated via GPCRs. One study described that 3-T\(_1\)AM-induced decrease of body temperature still persisted in mTaar1 knockout mice (5), which suggested that the actions of 3-T\(_1\)AM are not only mediated via the mTaar1 receptor for the induction of hypothermia (18). Recently, it has been shown that hypothermic effects of 3-T\(_1\)AM in mice are due to peripheral vasodilation and subsequent heat loss from the tail surface. Although the possible targets of 3-T\(_1\)AM, Taar1, and the adrenergic receptors were detected in tail arteries and the aorta, neither vessel responded to high doses of 3-T\(_1\)AM. As this anapyrexia effect was also found after intracerebroventricular injection, the authors concluded that this temperature effect might be mediated by non-GPCR targets such as TRPs in the hypothalamus (19). Notably, the systemic temperature lowering effect of 3-T\(_1\)AM lies within the range adequate for eliciting TRP activation. Application of specific blockers as well as overexpression system revealed the involvement of thermo-TRPs in 3-T\(_1\)AM-induced effect. Table 1 summarizes the effects of 3-T\(_1\)AM on Ca\(^{2+}\) regulation and whole-cell currents in different cell types. Notably, 3-T\(_1\)AM-induced Ca\(^{2+}\) influx varies between normal and neoplastic cells, whereas no differences were detected in whole-cell current densities. This indicates that cytosolic Ca\(^{2+}\) regulation induced by 3-T\(_1\)AM might be partially independent from TRP activities. In the following chapter, we summarize the current knowledge about TRP involvement in 3-T\(_1\)AM-induced Ca\(^{2+}\) mobilization and downstream signaling.

### Transient Receptor Potential Channels

Transient receptor potential channels (TRPs) are a superfamily of membrane-spanning non-selective cation channels, which are mainly permeated by Ca\(^{2+}\). Classically, TRPs can trigger pain and reception to temperature via nociceptors. The TRP superfamily includes 28 members, which can be subdivided into six groups in mammals based on sequence homology (20) and sensitivity to activation by different stimuli: TRPA (ankyrin), TRPC (canonical), TRPM (melastatin), TRPML (mucolipin), TRPP (polycystic), and TRPV (vanilloid) [reviewed in Ref. (21, 22)].

### Table 1 | 3-T\(_1\)AM effects in different cell types.

| [3-T\(_1\)AM] (µM) | Fluorescence ratio (f\(_{340\text{nm}}\)/f\(_{380\text{nm}}\)) | Inward currents (pA/pF) | Outward currents (pA/pF) | Expression localization (cell type) |
|-----------------|---------------------------------|------------------------|------------------------|-----------------------------------|
| 1.0             | ![increase](#)                   | N/A                    | N/A                    | TRPM8 transfected osteosarcoma [U2OS] (56) |
| 1.0             | ![increase](#)                   | N/A                    | N/A                    | Thyroid [PCCL3] (10)              |
| 1.0             | ![increase](#)                   | ![increase](#)        | 108                    | Human corneal epithelium [HCEC] (56) |
| 1.0             | ![increase](#)                   | ![increase](#)        | 161                    | Human conjunctival epithelium [HOC] (17) |
| 1.0             | ![increase](#)                   | ![increase](#)        | 170                    | Neuroendocrine tumor [BON-1] (unpubl.) |
| 5.0             | ![increase](#)                   | ![increase](#)        | 142                    | Uveal melanoma [92.1] (unpubl.)   |

Fluorescent Ca\(^{2+}\) indicator fura-2 is alternately excited at 340 and 380 nm, and the fluorescence ratio (f\(_{340\text{nm}}\)/f\(_{380\text{nm}}\)) is a relative index of changes in [Ca\(^{2+}\)]\(_\text{i}\).

† Slight increase, †† moderate increase, ††† strong increase, and †††† very strong increase.

3-T\(_1\)AM, 3-iodothyronamine; TRPM8, transient receptor potential channel melanatin 8.
TRPs are located in the plasma membrane and the membrane of various organelles of most cell types. These channels mainly function as homo- and heterotetrameric structures (23, 24). They share the same basic topology, consisting of six transmembrane domains, a pore-forming loop and intracellular N and C termini. In some, but not all subfamilies, the N terminal domain contains ankyrin repeats, which contribute to channel assembly as well as gating and is a common protein–protein interaction motif (25, 26).

TRPs can be activated by thermal, mechanical, or chemical stimuli ranging from ions to small molecules. They are able to integrate and transduce them into appropriate responses in excitable and non-excitable cells (27, 28). There is also some evidence that TRP-elicited responses are modulated by their interactions with other receptors, such as GPCRs or ion channels in various healthy cell types as well as tumor cells (29–31).

TRP/GPCR Interaction

In mammals, GPCRs and TRPs are coexpressed in a variety of cell types; and different signaling intermediates, such as adaptor proteins, kinases and lipid metabolites, functionally link GPCRs to TRPs (32). TRPs are major downstream effectors of GPCRs, and the signaling pathways that emanate from the activation of GPCRs lead to altered TRP activity or expression (22, 33). Profound understanding of the intracellular Ca²⁺ signaling network, particularly the TRP/GPCR cross-talk and the substantial roles of TRPs, has significantly advanced the field of drug design and development (33, 34). One of the most studied GPCR/TRP regulatory pathways includes the bradykinin receptor (BR), which is coexpressed with TRPV1, TRP ankyrin receptor 1 (TRPA1), TRPM8, and TRPV4 in DRG nerve terminals. Activation of BR leads to rapid stimulation of TRPs to evoke action potentials, resulting in pain and inflammation (32, 35). Another example is coexpression and interaction of muscarinic receptors and TRPV1 in idiopathic overactive bladder urothelial cells where the cells are responsive to both acetylcholine and capsaicin (36). Interestingly, 3-T,AM has been described as a novel antagonist of muscarinic type 3 receptor (37). Although further research on the potential pharmacological effects of 3-T,AM in this context is necessary, this interesting example emphasizes the possibility of targeting the TRP/GPCR axis to develop new therapeutic options for different diseases.

ROLE OF TRPs IN THERMOREGULATION

Six members of the TRP superfamily are recognized as temperature-sensitive TRPs (thermo-TRPs), which are activated at specific temperatures in the range from noxious heat to painful cold (38). Thermo-TRPs are believed to be involved in body temperature perception and based on response patterns can be divided into two subtypes; namely, cold and heat receptors. TRPV1 and TRPV2 respond to painful increases in temperature, while TRPV3 and TRPV4 respond to non-painful increases in temperature. TRPM2 is known as the hypothalamic heat sensor, which mediates the responses to the temperature above 37°C and modulates fever temperature (39). TRPM8 is activated by non-painful decreases in temperature and TRPA1 by painful decrease in temperatures (40, 41). Thermo-TRPs are also substrates of chronic inflammatory mediators released in pathological pain states, which contribute to inflammatory responses and neuropathic pain (42–45). Recent studies demonstrated that TRPM8 and TRPV1 play homeostatic roles in temperature regulation (34).

TRPV1 is the most eminent member of TRP superfamily and has a broad distribution in central and peripheral nervous systems (46). Expression of TRPV1 also has been observed in non-excitable cells (47–49). Generally, TRPV1 can be activated by various stimuli such as heat, vanilloids, cannabinoids, lipids, and protons (50, 51). Administration of TRPV1 agonists triggers both increased heat loss and heat production in mammals (52).

TRP melastatin 8 is found on Aδ and C fiber afferents and is a major determinant of temperature homeostasis including autonomic thermogenesis (30). TRPM8 can be activated by moderate cooling as well as a variety of chemical agonists that are known to produce cool sensations such as menthol and icilin (53–55).

In general, thermo-TRPs can be activated within specific temperature ranges and transduce such inputs into chemical and electrical signals. Different chemical agents are identified which target these channels and elicit the similar downstream effects. So far, 3-T,AM is the only known endogenous compound inducing hypothermia and suggested to modulate thermo-TRPs as described in the following paragraph.

3-T,AM INTERACTS WITH THERMO-TRPs

In a recent study, activation of warm-sensitive TRPM2 led to a similar thermoregulatory response observed in mice after systemic administration of 3-T,AM (19, 39). An electrophysiological screening of current densities in rat thyrocyte (PCCL3 cells) demonstrated the presence of thermo-TRPs in these cell lines. In PCCL3 cells, 3-T,AM induces Ca²⁺ responses similar to specific TRPM8 agonists such as menthol and icilin. Notably, Ca²⁺ elevation was exclusively attenuated in the presence of specific TRPM8 blocker (BCTC) in these cells, which strongly suggests 3-T,AM-induced Ca²⁺ rise is attributable to interactions with TRPM8 channels. Recent observations also confirmed the association between TRPM8 and 3-T,AM using an osteosarcoma heterologous expression system with overexpressed TRPM8 (56). Furthermore, many studies have demonstrated the endogenous expression of TRPs as well as adrenergic receptors in ocular tissues (17, 56–58). Interestingly, 3-T,AM evoked Ca²⁺ mobilization and increases in whole-cell currents in human conjunctival and corneal epithelial cells. This increase in Ca²⁺ influx and in- and outward whole-cell currents were almost fully attenuated in the presence of TRPM8 antagonists (10, 17, 56). Notably, the non-selective adrenergic receptor blocker timolol attenuated 3-T,AM-induced Ca²⁺ effects in a similar manner to BCTC, which suggested that 3-T,AM activates TRPM8 downstream of GPCRs such as β2 adrenergic receptors (7). Immunostaining pattern indicated TRPM8 expression in ER of ocular cells (17, 56). Previous studies also demonstrated TRPM8 localization in the ER membrane of a prostate cancer-derived epithelial cell line (LNCaP) (59, 60). Consequently, TRPM8 has been suggested as an important ER Ca²⁺ release channel, which is involved in numerous processes in prostate cancer epithelial cells (60). Therefore, the persistence of 3-T,AM-induced Ca²⁺ influx in extracellular Ca²⁺...
free conditions also might be attributable to intracellular TRPM8 expression in epithelial cells, which supports the hypothesis of 3-T1AM-induced Ca\(^{2+}\) influx downstream of GPCRs.

Taken together, recent studies suggest that 3-T1AM acts as a cooling agent similar to menthol or icilin. It has been proposed that 3-T1AM may be a ligand of TRPM8; however, the evidence suggests that its cooling actions are primarily mediated via GPCR activation, which indirectly modulates TRPM8 activity. There is accumulating evidence that thermo-TRPs such as TRPM8 and TRPV1 are not only involved in physiological regulations but also a variety of pathophysiological conditions such as inflammation can be influenced by activation of these channels. Here, we describe the role of TRPs in inflammation and the potential of 3-T1AM as an anti-inflammatory agent.

**ROLE OF TRPs IN INFLAMMATION**

Different studies have demonstrated the role of TRPM8 in mediating the anti-inflammatory effects of mild cooling in trauma-induced peripheral inflammation and limiting pain sensation after injury (61, 62). Menthol is one of the most commonly used phytochemical compounds in our daily life due to its analgesic benefit and its ability to provide a cooling sensation (63). Coexpression of TRPV1 with TRPM8 has been demonstrated in many different cell types (64, 65). It is known that multiple inflammatory signaling pathways can be activated downstream of TRPV1 activation by exogenous and endogenous stimuli (66, 67). Capsaicin as a specific TRPV1 agonist elicits increases in pro-inflammatory cytokine release via intracellular Ca\(^{2+}\) transients, which leads to interleukin secretion (68, 69). The interdependence of TRPM8 and TRPV1 ion channel function has raised interest in the field of anti-inflammatory therapeutic research (70, 71). Previous studies have shown that menthol blocks the mechanical and heat hyperalgesia caused by injection of inflammatory compounds, such as capsaicin (72, 73). Icilin is another specific TRPM8 agonist that is known as a “super-cooling” agent, with a notably higher potency and efficacy than menthol in cellular and behavioral studies (55). Icilin attenuates TRPV1-dependent calcitonin gene-related peptide release in the colon and is a promising therapeutic target for the treatment of colitis (71). Another study also suggested that downregulation of TRPM8 aggravates TRPV1-mediated inflammatory hyperalgesia (70). Although, the recent drug-screening efforts targeting TRPs have resulted in the discovery of effective TRPM8 agonists, the majority of these drugs either were not clinically efficacious or displayed adverse side effects. Subsequently, the general interest for introducing an effective and safe TRP modulator to suppress inflammatory symptoms in different tissues has increased. Recent studies demonstrated that 3-T1AM has promising anti-inflammatory cooling properties similar to cooling agents such as icilin (17, 56).

**3-T1AM, A POSSIBLE THERAPEUTIC OPTION FOR INFLAMMATION?**

It has been well-established that TRPM8 activation leads to the suppression of TRPV1 stimulation (70, 71). Thus, we reviewed here the role of 3-T1AM in this feedback system. Interestingly, an inverse association between changes in TRPM8 and TRPV1 activity after 3-T1AM stimulation has been observed. Specifically, 3-T1AM blocked capsaicin-induced TRPV1 activation in human conjunctival and corneal epithelial cell lines and attenuated downstream rises in IL-6 release (17, 56). It was previously described that a TRPV1 antagonist elicited suppression of injury-induced stromal TRPV1 activation in corneal epithelium, which reduced inflammation and fibrosis (74). Notably, the blunting effects of 3-T1AM on TRPV1-induced Ca\(^{2+}\) influx and IL-6 release mirrored the effects of TRPV1 specific inhibitor (17, 56). This observation revealed a potential therapeutic value of 3-T1AM for suppressing TRPV1-induced Ca\(^{2+}\) channel-mediated inflammatory processes in different pathophysiological conditions such as dry eye syndrome.

**CONCLUSION**

The TH derivative 3-T1AM has been identified as a novel endogenous signaling compound exhibiting remarkable physiological effects such as hypothermia and hyperglycemia, as well as promising therapeutic potential in the experimental prophylaxis and treatment of stroke. Currently, the underlying mechanism of 3-T1AM action and its physiological receptor(s) have been insufficiently characterized and are in need of further research. Here, we reviewed the Ca\(^{2+}\) signal transduction pathways induced by 3-T1AM and provided the promising evidence of TRP channel modulation through this TH metabolite (Figure 1). The 3-T1AM action on GPCRs as well as on TRPs indicates the complex functional (co)-regulation of each system, which have a high impact on physiological and pathophysiological conditions. The close crosstalk of GPCRs and TRPs provides the opportunity to widen the options for therapeutic intervention, and by using such coregulated systems the possibility of unwanted side effects might be reduced.

**AUTHOR CONTRIBUTIONS**

NK and HB contributed to the conception, design, and drafting of this review. NK created the figure. SM created the table and contributed to the conception of this review. All the authors read and approved the final manuscript.

**ACKNOWLEDGMENTS**

The authors appreciate very much the input of Heiko Krude (Institute for Experimental Pediatric Endocrinology, Charite, University-Medicine Berlin) and his very helpful discussion. We thank the special support for editing the manuscript provided by Nicole Hallahan.

**FUNDING**

This work received a grant from the DFG priority program ThyroidTransAct (BI893/5-2). SM is supported by DFG (ME1706/14-1, ME1706/18-1) concerning TRP channel related research projects.
REFERENCES

1. Scanlan TS, Suchland KL, Hart ME, Chieffini G, Huang Y, Krujich PJ, et al. 3-Iodothyronine is an endogenous and rapid-acting derivative of thyroid hormone. *Nat Med* (2004) 10(6):638–42. doi:10.1038/nm1051

2. Kleinau G, Khajavi N, Kheir I, Biebbern M. Differential modulation of adrenergic receptor signaling by octopamine, tyramine, phenylethylamine, and 3-iodothyronine. *Trends in Neurosciences* (2016) 2:63. doi:10.1016/B978-0-12-803603-7.00005-7

3. Pielh S, Hoeig C, Scanlan T, Kohrie J. Thromboxanes – past, present, and future. *Endocr Rev* (2010) 31(1):64–80. doi:10.1210/er.2009-0040

4. Zucchi R, Chieffini G, Scanlan T, Grandy D. Trace amine-associated receptors and their ligands. *Br J Pharmacol* (2006) 149(8):967–78. doi:10.1038/sj.bjp.0706948

5. Zucchi R, Accorroni A, Chieffini G. Update on 3-iodothyronine and its neurological and metabolic actions. *Front Physiol* (2014) 5:402. doi:10.3389/fphys.2014.00402

6. Dinter J, Mühllhaus J, Jacoby SF, Wiensch CL, Cöster M, Meister J, et al. Novel thryoxine derivatives, thyronamine and 3-iodothyronamine. *Mol Cell Endocrinol* (1991) 81(1):175–83. doi:10.1016/0303-7207(90)90055-4

7. Dinter J, Mühlhaus J, Jacobi SF, Wiensch CL, Cöster M, Hermsdorff T, et al. 3-Iodothyronamine differentially modulates α2A-adrenergic receptor-mediated signaling. *J Mol Endocrinol* (2015) 54(3):205–16. doi:10.1530/JME-15-0003

8. Dinter J, Khajavi N, Mühllhaus J, Wiensch CL, Cöster M, Hermsdorf T, et al. The multitarget ligand 3-iodothyronamine modulates β-adrenergic receptor 2 signaling. *Eur Thyroid J* (2015) 4(Suppl 1):21–9. doi:10.1111/etj.12100

9. Kliever LP, Foppen E, Ackermans MT, Serlie MJ, Sauwerin HP, Scanlan TS, et al. Central thryoxine sensitivity metabolic modulation in rats. *J Endocrinol* (2009) 203(3):377–86. doi:10.1677/JOE-09-0043

10. Doyle KP, Suchland KL, Ciesielski TM, Lesov NS, Grandy DK, Scanlan TS, et al. Novel thryoxine derivatives, thrymonine and 3-iodothyronine, induce transient hypothermia and marked neuroprotection against stroke injury. *Stroke* (2007) 38(9):2569–76. doi:10.1161/STROKEAHA.107.500378

11. Schanze N, Jacoby SF, Rintjes E, Mergler S, del Olmo M, Hoeig CS, et al. 3-Iodothyronine decreases expression of genes involved in iodide metabolism in mouse thyroids and inhibits iodide uptake in PCC3L thyocytes. *Thyroid* (2017) 27(1):11–22. doi:10.1089/thy.2016.0182

12. Laurent E, Moskel J, Van Sande J, Graff J, Dumont JE. Dual activation by thrynotropin of the phospholipase C and cyclic AMP cascades in human thyroid. *Mol Cell Endocrinol* (1987) 52(3):273–8. doi:10.1016/0303-7207(87)90055-4

13. Dumont JE, Willems C, Sande J, Né P. Regulation of the release of thyroid hormones: role of cyclic AMP. *Ann N Y Acad Sci* (1971) 185(1):291–316. doi:10.1111/j.1749-6632.1971.tb45255.x

14. Grasberger H, Van Sande J, Hagh-Dahouh Mahameed A, Tenenbaum-Rakover Y, Clapham DE. TRP channels as cellular sensors. *Trends Endocrinol Metab* (2002) 13(8):319–24. doi:10.1016/S0968-0004(99)01426-7

15. Voets T. Quantifying and modeling the temperature-dependent gating of TRP channels. *Rev Physiol Biochem Pharmacol* (2012) 162:91–119. doi:10.1007/1112_2011_5

16. Khajavi N, Reinach PS, Slavi N, Skrzypski M, Lucius A, Strauss O, et al. Novel thyroxine derivatives, thyronamine and 3-iodothyronamine. *Nature* (2002) 418(6894):181–6. doi:10.1038/nature00882

17. Reeh PW, Kheir I, Biebbern M. Sensory and signaling mechanisms of bradykinin, eicosanoids, platelet-activating factor, and nitric oxide in peripheral nociceptors. *Exp Eye Res* (2012) 94(4):1699–775. doi:10.1016/j.exer.2012.02.002

18. Pethö G, Reeh PW. Sensory and signaling mechanisms of bradykinin, eicosanoids, platelet-activating factor, and nitric oxide in peripheral nociceptors. *Physiol Rev* (2012) 92(4):1699–775. doi:10.1152/physrev.00048.2010

19. Veldhuis NA, Poole DP, Grace M, McIntyre P, Bunnnett NW. The G protein-coupled receptor-transient receptor potential channel axis: molecular insights for targeting disorders of sensation and inflammation. *Pharmacol Rev* (2015) 67(1):36–73. doi:10.1111/pr.12405

20. Ahern GP. Transient receptor potential channels and energy homeostasis. *Trends Endocrinol Metab* (2013) 24(11):554–60. doi:10.1016/j.tem.2013.06.005

21. Ramírez S, Kheir I, Biebbern M. Sensory and signaling mechanisms of bradykinin, eicosanoids, platelet-activating factor, and nitric oxide in peripheral nociceptors. *J Biol Chem* (2002) 277(50):47034–41. doi:10.1074/jbc.M206496200

22. Clapham DE. TRP channels as cellular sensors. *Annu Rev Physiol* (2005) 67:1749–6632.1971.tb45255.x

23. Ramsey IS, Delling M, Clapham DE. An introduction to TRP channels. *Annu Rev Physiol* (2015) 77:57–72. doi:10.1146/annurev.physiol.050714.033525

24. Montec C. The TRP superfamily of cation channels. *Sci Signal* (2005) 2005(272):re3. doi:10.1126/science.2722005re3

25. Pan S, Yang H, Reinch LA. Transient receptor potential (TRP) gene superfamily encoding cation channels. *Hum Genomics* (2011) 5(2):108. doi:10.1186/1479-7364-5-2-108

26. Ramírez S, Kheir I, Biebbern M. Sensory and signaling mechanisms of bradykinin, eicosanoids, platelet-activating factor, and nitric oxide in peripheral nociceptors. *J Biol Chem* (2002) 277(50):47034–41. doi:10.1074/jbc.M206496200

27. Akbar A, Yiangou Y, Facer P, Walters JR, Anand P, Ghosh S. Increased capsaicin receptor TRPV1 expressing sensory fibres in irritative bowel syndrome and.
their correlation with abdominal pain. Gut (2008) 57(7):923–9. doi:10.1136/gut.2007.138982

43. Engler A, Aeschlimann A, Simmen BR, Michel BA, Gay RE, Gay S, et al. Expression of transient receptor potential vanilloid 1 (TRPV1) in synovial fibroblasts from patients with osteoarthritis and rheumatoid arthritis. Biochem Biophys Res Commun (2007) 359(4):884–8. doi:10.1016/j.bbrc.2007.05.178

44. Yamamura H, Ugawa S, Ueda T, Morita A, Shimada S. TRPM8 activation suppresses cellular viability in human melanoma. Am J Physiol Cell Physiol (2008) 295(2):C229–301. doi:10.1152/ajpcell.00499.2007

45. Wondergem R, Bartley JW. Menthol increases human glioblastoma intracellular Ca2+. BK channel activity and cell migration. J Biomed Sci (2009) 16(1):90. doi:10.1186/1423-0127-16-90

46. Martins D, Tavares I, Morgado C. “Hotheaded”: the role of TRPV1 in brain functions. Neuropharmacology (2014) 85:151–7. doi:10.1016/j.neuropharm.2014.05.034

47. Akiba Y, Kato S, Katsube K-I, Nakamura M, Takeuchi K, Ishii H, et al. Transient receptor potential vanilloid subfamily 1 expressed in pancreatic islet β cells modulates insulin secretion in rats. Biochem Biophys Res Commun (2004) 321(1):219–25. doi:10.1016/j.bbrc.2004.06.149

48. Mergler S, Garreis F, Sahlmüller M, Lyras E-M, Reinach PS, Dwarakanath A, et al. Calcium regulation by thermo- and osmosensing transient receptor potential vanilloid channels (TRPVs) in human conjunctival epithelial cells. Histochem Cell Biol (2012) 137(6):743–61. doi:10.1007/s00418-012-0924-5

49. Yang Y, Yang H, Wang Z, Mergler S, Wolosin JM, Reinach PS. Functional TRPV1 expression in human corneal fibroblasts. Exp Eye Res (2013) 107:121–9. doi:10.1016/j.exer.2012.11.004

50. Fernandes E, Fernandes M, Kebbe J. The functions of TRPA1 and TRPV1: moving away from sensory nerves. Br J Pharmacol (2012) 166(2):510–21. doi:10.1111/j.1476-5381.2012.01851.x

51. Pingle S, Matta J, Ahern G. Capsaicin receptor: TRPV1 a promiscuous TRP channel. Handb Exp Pharmacol (2007) 179:155–71. doi:10.1007/978-3-540-43817-9_7

52. Kobayashi A, Osaka T, Namba Y, Inoue S, Lee TH, Kimura S. Capsaicin activates heat loss and heat production simultaneously and independently in rats. Am J Physiol (1998) 275(1):R82–8.

53. Behrendt HJ, Germann T, Gillen C, Hatt H, Jostock R. Characterization of the mouse cold-menthol receptor TRPM8 and vanilloid receptor type-1 VR1 using a fluorometric imaging plate reader (FLIPR) assay. Br J Pharmacol (2004) 141(4):737–43. doi:10.1038/sj.bjp.0705652

54. Dai Y. TRPs and pain. Semin Immunopathol (2016) 38(3):277–91. doi:10.1007/s00281-015-0526-0

55. McKemy DD, Neuhauser WM, Julius D. Identification of a cold receptor reveals a general role for TRP channels in thermosensation. Nature (2002) 416(6876):52–8. doi:10.1038/nature00719

56. Lucas A, Khajavi N, Reinach PS, Köhrle J, Dhandapani P, Huimann P, et al. 3-Iodothyronamine increases transient receptor potential melastatin channel 8 (TRPM8) activity in immortalized human corneal epithelial cells. Cell Signal (2016) 28(3):136–47. doi:10.1016/j.cellsig.2015.12.005

57. Matsuo T, Cynader MS. Localization of alpha-2 adrenergic receptors in the human eye. Ophthalmic Res (1992) 24(4):213–9. doi:10.1159/00026170

58. Neufeld AH, Zawistowski K, Page ED, Bromberg BB. Influences on the density of beta-adrenergic receptors in the human eye. Ophthalmic Res (1992) 24(4):213–9. doi:10.1159/00026170

59. Neufeld AH, Zawistowski K, Page ED, Bromberg BB. Influences on the density of beta-adrenergic receptors in the human eye. Ophthalmic Res (1992) 24(4):213–9. doi:10.1159/00026170

60. Pham C, Cota J, Sauer M, Min J-W, Chung C, Uhl GR, et al. The regulation of TRPM8 activity in human limbal epithelial cells. PLoS One (2015) 10(12):e0142653. doi:10.1371/journal.pone.0142653

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2017 Khajavi, Mergler and Biebermann. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.